Literature DB >> 25823618

Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients.

Yan-mei Jiao1, Wen-jia Weng1, Quan-sheng Gao2, Wei-jun Zhu3, Wei-ping Cai4, Ling-hua Li4, Hong-jun Li5, Yan-qing Gao6, Hao Wu7.   

Abstract

This study investigated whether treatment with IFN-α and ribavirin (RBV) reduces 2LTR circular HIV DNA in addition to the total and integrated HIV DNA. Two groups of patients were enrolled. Group 1 comprised HIV/HCV co-infected patients who were treated with highly active antiretroviral therapy (HAART), IFN-α and RBV for 48 weeks. After the 48 weeks of treatment, IFN-α and RBV treatment was discontinued and HAART was continued. Group 2 comprised HIV-infected patients who were treated with HAART. Real-time polymerase chain reaction (RT-PCR) was used to quantify the levels of HIV-1 DNA. We found that compared with Group 2 patients, Group 1 patients exhibited an obvious decrease in the CD4 cell count and the total DNA, 2LTR circular DNA, and integrated HIV DNA after 48 weeks of treatment. After the discontinuation of IFN-α and RBV treatment in Group 1 patients, the levels of HIV DNA recovered. Therefore, we concluded that treatment with IFN-α and ribavirin (RBV) reduces 2LTR circular HIV DNA.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2LTR circular HIV DNA; HCV; HIV; IFN-α

Mesh:

Substances:

Year:  2015        PMID: 25823618     DOI: 10.1016/j.antiviral.2015.03.011

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  13 in total

1.  Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy.

Authors:  Shane D Falcinelli; Bonnie E Shook-Sa; Morgan G Dewey; Sumati Sridhar; Jenna Read; Jennifer Kirchherr; Katherine S James; Brigitte Allard; Simon Ghofrani; Erin Stuelke; Caroline Baker; Nadia R Roan; Joseph J Eron; JoAnn D Kuruc; Catalina Ramirez; Cynthia Gay; Katie R Mollan; David M Margolis; Adaora A Adimora; Nancie M Archin
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

2.  Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Authors:  Stéphane Hua; Selena Vigano; Samantha Tse; Ouyang Zhengyu; Sean Harrington; Jordi Negron; Pilar Garcia-Broncano; Giulia Marchetti; Miguel Genebat; Manuel Leal; Salvador Resino; Ezequiel Ruiz-Mateos; Mathias Lichterfeld; Xu G Yu
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079

3.  NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Andrew V Kossenkov; Noor Dawany; Knashawn H Morales; Matthew Fair; Brian N Ross; Kenneth Lynn; Agnieszka Mackiewicz; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Jay R Kostman; Louise Showe; Luis J Montaner
Journal:  J Immunol       Date:  2019-06-28       Impact factor: 5.422

4.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

5.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

6.  Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.

Authors:  Sara Morón-López; Elisabet Gómez-Mora; Maria Salgado; Dan Ouchi; Maria C Puertas; Víctor Urrea; Jordi Navarro; Antoni Jou; Mercedes Pérez; Cristina Tural; Bonaventura Clotet; Luis J Montaner; Julià Blanco; Manuel Crespo; Javier Martinez-Picado
Journal:  J Infect Dis       Date:  2015-11-01       Impact factor: 5.226

7.  Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N Ross; Matthew Fair; Bonnie J Howell; Daria J Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R Kostman; Pablo Tebas; Luis J Montaner
Journal:  AIDS Res Hum Retroviruses       Date:  2021-01-29       Impact factor: 1.723

Review 8.  The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection.

Authors:  Bowen Wang; Wen Kang; Jiahui Zuo; Wenzhen Kang; Yongtao Sun
Journal:  Front Immunol       Date:  2017-11-01       Impact factor: 7.561

9.  Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.

Authors:  Gabriella Rozera; Gabriele Fabbri; Patrizia Lorenzini; Ilaria Mastrorosa; Laura Timelli; Mauro Zaccarelli; Alessandra Amendola; Alessandra Vergori; Maria Maddalena Plazzi; Stefania Cicalini; Andrea Antinori; Maria Rosaria Capobianchi; Isabella Abbate; Adriana Ammassari
Journal:  PLoS One       Date:  2017-10-27       Impact factor: 3.240

10.  Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy.

Authors:  Yanina Ghiglione; María Laura Polo; Alejandra Urioste; Ajantha Rhodes; Alejandro Czernikier; César Trifone; María Florencia Quiroga; Alicia Sisto; Patricia Patterson; Horacio Salomón; María José Rolón; Sonia Bakkour; Sharon R Lewin; Gabriela Turk; Natalia Laufer
Journal:  Open Forum Infect Dis       Date:  2020-04-02       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.